Applications of Immunogenomics to Cancer

Cancer immunogenomics originally was framed by research supporting the hypothesis that cancer mutations generated novel peptides seen as "non-self" by the immune system. The search for these "neoantigens" has been facilitated by the combination of new sequencing technologies, specialized computational analyses, and HLA binding predictions that evaluate somatic alterations in a cancer genome and interpret their ability to produce an immune-stimulatory peptide. The resulting information can characterize a tumor's neoantigen load, its cadre of infiltrating immune cell types, the T or B cell receptor repertoire, and direct the design of a personalized therapeutic.

[1]  H. Diao,et al.  Current status and recent advances of next generation sequencing techniques in immunological repertoire , 2016, Genes and Immunity.

[2]  B. Nelson,et al.  Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer , 2016, Clinical Cancer Research.

[3]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[4]  V. Giudicelli,et al.  IMGT(®) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. , 2012, Methods in molecular biology.

[5]  D. McNeel.  TCR diversity – a universal cancer immunotherapy biomarker? , 2016, Journal of Immunotherapy for Cancer.

[6]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[7]  Y. Nishimura,et al.  The present status and future prospects of peptide-based cancer vaccines. , 2016, International immunology.

[8]  Mikhail Shugay,et al.  MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.

[9]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[10]  M. Mann,et al.  Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.

[11]  Matthew D. Wilkerson,et al.  ABRA: improved coding indel detection via assembly-based realignment , 2014, Bioinform..

[12]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[13]  S. Stevanović,et al.  A vaccine targeting mutant IDH1 induces antitumour immunity , 2014, Nature.

[14]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[15]  R. Wilson,et al.  INTEGRATE: gene fusion discovery using whole genome and transcriptome data , 2016, Genome research.

[16]  Old Lj,et al.  Immunology of Experimental Tumors , 1964 .

[17]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[18]  Han Xu,et al.  MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes , 2014, Genome Biology.

[19]  Enkelejda Miho,et al.  Bioinformatic and Statistical Analysis of Adaptive Immune Repertoires. , 2015, Trends in immunology.

[20]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[21]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[22]  G. Cole.  Interferon-gamma ELISPOT assay for the quantitative measurement of antigen-specific murine CD8+ T-cells. , 2005, Methods in molecular biology.

[23]  Ludmila V. Danilova,et al.  Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[24]  Marie-Paule Lefranc,et al.  IMGT, the international ImMunoGeneTics database , 1999, Nucleic Acids Res..

[25]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[26]  V. Giudicelli,et al.  Correction: IMGT/HighV-QUEST Statistical Significance of IMGT Clonotype (AA) Diversity per Gene for Standardized Comparisons of Next Generation Sequencing Immunoprofiles of Immunoglobulins and T Cell Receptors , 2015, PloS one.

[27]  Sean C. Bendall,et al.  Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. , 2012, Immunity.

[28]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[29]  W. Gillanders,et al.  Personalized cancer vaccines: Targeting the cancer mutanome. , 2017, Vaccine.

[30]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[31]  C. Vollmers,et al.  Highly Accurate Sequencing of Full-Length Immune Repertoire Amplicons Using Tn5-Enabled and Molecular Identifier–Guided Amplicon Assembly , 2016, The Journal of Immunology.

[32]  Julia G. Bodmer,et al.  IMGT/HLA Database--a sequence database for the human major histocompatibility complex. , 2001, Nucleic acids research.

[33]  R. Emerson,et al.  High‐throughput sequencing of T‐cell receptors reveals a homogeneous repertoire of tumour‐infiltrating lymphocytes in ovarian cancer , 2013, The Journal of pathology.

[34]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[35]  E. J. Foley.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953, Cancer research.

[36]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[37]  Maxim N. Artyomov,et al.  Tumor neoantigens: building a framework for personalized cancer immunotherapy. , 2015, The Journal of clinical investigation.

[38]  J. Shabanowitz,et al.  The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68 , 1997, The Journal of experimental medicine.

[39]  Morten Nielsen,et al.  Peptide binding predictions for HLA DR, DP and DQ molecules , 2010, BMC Bioinformatics.

[40]  Evan Z. Macosko,et al.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets , 2015, Cell.

[41]  R. Fauchet,et al.  Presence on a human melanoma of multiple antigens recognized by autologous CTL , 1989, International journal of cancer.

[42]  J. Castle,et al.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.

[43]  R. Holt,et al.  Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. , 2009, Genome research.

[44]  L. Old,et al.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[45]  V. Greiff,et al.  A bioinformatic framework for immune repertoire diversity profiling enables detection of immunological status , 2015, Genome Medicine.

[46]  Jin Zhang,et al.  INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery , 2016, Bioinform..

[47]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[48]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[49]  Foley Ej.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953 .

[50]  Chittibabu Guda,et al.  A Comparison of Variant Calling Pipelines Using Genome in a Bottle as a Reference , 2015, BioMed research international.

[51]  J. Maguire,et al.  Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.

[52]  Jun Wang,et al.  Predicting tumor purity from methylation microarray data , 2015, Bioinform..

[53]  Benjamin Schubert,et al.  OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..

[54]  M. Schatz,et al.  Accurate detection of de novo and transmitted indels within exome-capture data using micro-assembly , 2014, Nature Methods.

[55]  Jason R. Myers,et al.  Comparison of insertion/deletion calling algorithms on human next-generation sequencing data , 2014, BMC Research Notes.

[56]  T. Tedder,et al.  B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice , 2010, The Journal of Immunology.

[57]  E. Appella,et al.  A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.

[58]  Zhenyu Xuan,et al.  Hybrid selection of discrete genomic intervals on custom-designed microarrays for massively parallel sequencing , 2009, Nature Protocols.

[59]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[60]  Kenji Satou,et al.  PAAQD: Predicting immunogenicity of MHC class I binding peptides using amino acid pairwise contact potentials and quantum topological molecular similarity descriptors. , 2013, Journal of immunological methods.

[61]  Yadong Wang,et al.  PRISM: Pair-read informed split-read mapping for base-pair level detection of insertion, deletion and structural variants , 2012, Bioinform..

[62]  Jedd D. Wolchok,et al.  Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.

[63]  Jian Ma,et al.  FusionHunter: identifying fusion transcripts in cancer using paired-end RNA-seq , 2011, Bioinform..

[64]  H. Robson MacDonald,et al.  GENERATION OF CYTOTOXIC T LYMPHOCYTES IN VITRO : I. RESPONSE OF NORMAL AND IMMUNE MOUSE SPLEEN CELLS IN MIXED LEUKOCYTE CULTURES , 1974 .

[65]  J. Sidney,et al.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity , 2014, The Journal of experimental medicine.

[66]  Pornpimol Charoentong,et al.  Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.

[67]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[68]  Ryan Emerson,et al.  CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.

[69]  Mikhail Pogorelyy,et al.  VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires , 2015, PLoS Comput. Biol..

[70]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[71]  P. Greenberg,et al.  The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. , 1990, Science.

[72]  P. Monach,et al.  A unique tumor antigen produced by a single amino acid substitution. , 1995, Immunity.

[73]  G. Yaari,et al.  Practical guidelines for B-cell receptor repertoire sequencing analysis , 2015, Genome Medicine.

[74]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[75]  E. Unanue,et al.  Binding of immunogenic peptides to Ia histocompatibility molecules , 1985, Nature.

[76]  Philip L. F. Johnson,et al.  A population biological approach to understanding the maintenance and loss of the T‐cell repertoire during aging , 2014, Immunology.

[77]  O. Britanova,et al.  VDJviz: a versatile browser for immunogenomics data , 2016, BMC Genomics.

[78]  Joel S. Parker,et al.  Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V’DJer , 2016, Bioinform..

[79]  Christopher Ricks,et al.  To J.S. , 2014 .

[80]  Bjoern Peters,et al.  A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population , 2013, Immunogenetics.

[81]  Kendall A. Smith,et al.  Long term culture of tumour-specific cytotoxic T cells , 1977, Nature.

[82]  Allon M. Klein,et al.  Droplet Barcoding for Single-Cell Transcriptomics Applied to Embryonic Stem Cells , 2015, Cell.

[83]  Shameek Ghosh,et al.  Hybrid biogeography based simultaneous feature selection and MHC class I peptide binding prediction using support vector machines and random forests. , 2013, Journal of immunological methods.

[84]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[85]  Richard A. Moore,et al.  Derivation of HLA types from shotgun sequence datasets , 2012, Genome Medicine.

[86]  Marie-Paule Lefranc,et al.  IMGT, the international ImMunoGeneTics database , 1997, Nucleic Acids Res..

[87]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[88]  Angie Duy Vo,et al.  Identifying fusion transcripts using next generation sequencing , 2016, Wiley interdisciplinary reviews. RNA.

[89]  J. Kaplan,et al.  Enhanced Efficacy of Melanoma Vaccines in the Absence of B Lymphocytes , 2004, Journal of immunotherapy.

[90]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[91]  P. Chomez,et al.  Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[92]  James Robinson,et al.  The IMGT/HLA database , 2008, Nucleic Acids Res..

[93]  F. Marincola,et al.  Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors , 2013, Journal of Immunotherapy for Cancer.

[94]  B. Nelson,et al.  CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes , 2010, The Journal of Immunology.

[95]  E. Mardis.  DNA sequencing technologies: 2006–2016 , 2017, Nature Protocols.

[96]  Aakrosh Ratan,et al.  Identification of indels in next-generation sequencing data , 2015, BMC Bioinformatics.

[97]  Ö. Türeci,et al.  Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination , 2015, Journal of immunology research.

[98]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[99]  Alessandro Sette,et al.  Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method , 2005, BMC Bioinformatics.

[100]  Andrei L. Turinsky,et al.  The missing indels: an estimate of indel variation in a human genome and analysis of factors that impede detection , 2015, Nucleic acids research.

[101]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[102]  Ludmila V. Danilova,et al.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[103]  Axel Hoos,et al.  Classification of current anticancer immunotherapies , 2014, Oncotarget.

[104]  Morten Nielsen,et al.  Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers , 2008, Bioinform..

[105]  D. Wiley,et al.  Structure of the human class I histocompatibility antigen, HLA-A2. , 2005, Journal of immunology.

[106]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[107]  J. Calis,et al.  Characterizing immune repertoires by high throughput sequencing: strategies and applications. , 2014, Trends in immunology.

[108]  Bo Li,et al.  A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data , 2014, Genome Biology.

[109]  Mads Thomassen,et al.  Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data , 2016, PloS one.

[110]  M. Dimon,et al.  An Efficient Method for Identifying Gene Fusions by Targeted RNA Sequencing from Fresh Frozen and FFPE Samples , 2015, PloS one.

[111]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[112]  J. Wolchok,et al.  Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.

[113]  Kristina M. Ilieva,et al.  IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin , 2016, Scientific Reports.

[114]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[115]  J. Kitzman,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Whole exome capture in solution with 3Gbp of data , 2010 .

[116]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[117]  Morten Nielsen,et al.  The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding , 2009, Bioinform..

[118]  Jun S. Liu,et al.  Landscape of tumor-infiltrating T cell repertoire of human cancers , 2016, Nature Genetics.

[119]  S. Qiu,et al.  Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[120]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[121]  Xiaoping Zhou,et al.  Distribution and significance of interstitial fibrosis and stroma-infiltrating B cells in tongue squamous cell carcinoma , 2016, Oncology letters.

[122]  Morten Nielsen,et al.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..

[123]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[124]  Morten Nielsen,et al.  Pan-Specific Prediction of Peptide–MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity , 2016, The Journal of Immunology.

[125]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[126]  C. Desmarais,et al.  T cell repertoire following autologous stem cell transplantation for multiple sclerosis. , 2014, The Journal of clinical investigation.

[127]  Mikhail Shugay,et al.  Towards error-free profiling of immune repertoires , 2014, Nature Methods.

[128]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[129]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  H. Robins.  Immunosequencing: applications of immune repertoire deep sequencing. , 2013, Current opinion in immunology.

[131]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[132]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[133]  D. Campana,et al.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[134]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[135]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[136]  James Robinson,et al.  IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex , 2003, Nucleic Acids Res..